Associate Professor of Medicine, University Tex Houston
Oncology
Dr. Nizar M. Tannir, MD
|
|
Give Review
Dr. Nizar M. Tannir practices Oncology. He received awards:"Top Doctors:SE Texas". Nizar Tannir is also a published doctor. He has 96 paper published. The most recent paper is: Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Can the spinal instability neoplastic score prior to spinal radiosurgery predict compression fractures following stereotactic spinal radiosurgery for metastatic spinal...
- Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations.
- Gene-environment interaction of genome-wide association study-identified susceptibility loci and meat-cooking mutagens in the etiology of renal cell Carcinoma.
- Outcomes of Unselected Patients with Metastatic Clear-Cell Renal Cell Carcinoma Treated with Front-Line Pazopanib Therapy Followed by Vascular Endothelial Growth Facto...
- Osseous Pseudoprogression in Vertebral Bodies Treated with Stereotactic Radiosurgery: A Secondary Analysis of Prospective Phase I/II Clinical Trials.
- Surgical Management for Local Retroperitoneal Recurrence Of Renal Cell Carcinoma After Radical Nephrectomy.
- Role of partial nephrectomy as cytoreduction in the management of metastatic renal cell Carcinoma.
- Posttraumatic stress and depressive symptoms in renal cell Carcinoma: association with quality of life and utility of single-item distress screening.
- Multilevel-analysis identify a cis-expression quantitative trait locus associated with risk of renal cell Carcinoma.
- MET abnormalities in patients with genitourinary Malignancies and outcomes with c-MET inhibitors.
- Clinically nonmetastatic renal cell Carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent.
- Characterization of long non-coding RNA transcriptome in clear-cell renal cell Carcinoma by next-generation deep sequencing.
- Proteinuria with first-line therapy of metastatic renal cell Cancer.
- Mitochondrial DNA Copy Number in Peripheral Blood Leukocytes and the Risk of Clear Cell Renal Cell Carcinoma.
- Neuroendocrine Tumors of the kidney: a single institution experience.
- Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab.
- Phase I Trial of Sunitinib and Temsirolimus in Metastatic Renal Cell Carcinoma.
- Incidence and Predictive Factors of Pain Flare After Spine Stereotactic Body Radiation Therapy: Secondary Analysis of Phase 1/2 Trials.
- Outcomes of Adults With Ewing Sarcoma Family of Tumors (ESFT) of the Kidney: A Single-Institution Experience.
- Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate Cancer.
- Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell Carcinoma.
- Autophagy mediates HIF2α degradation and suppresses Renal tumorigenesis.
- Psychological states, serum markers and survival: associations and predictors of survival in patients with renal cell Carcinoma.
- Next generation sequencing of translocation renal cell Carcinomas reveals novel RNA splicing partners and frequent mutations of chromatin remodeling genes.
- The scientific method: pillar and pitfall of Cancer research.
- Collision tumor of the kidney composed of clear cell Carcinoma and collecting duct Carcinoma: report of a case with unusual morphology and clinical follow up.
- Randomized controlled trial of expressive writing for patients with renal cell Carcinoma.
- Partial nephrectomy in the setting of metastatic renal cell Carcinoma.
- Phase 2 Trial of Neoadjuvant Axitinib in Patients with Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma.
- Outcomes of Patients With Metastatic Renal Cell Carcinoma and End-Stage Renal Disease Receiving Dialysis and Targeted Therapies: A Single Institution Experience.
- Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK.
- Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Alternative Sunitinib Schedules.
- mTOR inhibitor associated noninfectious pneumonitis in patients with renal cell Cancer: management, predictors, and outcomes.
- Genomic Heterogeneity of Translocation Renal Cell Carcinoma.
- Outcomes of patients with metastatic clear-cell renal cell Carcinoma treated with pazopanib after disease progression with other targeted therapies.
- Curability of Poor-Risk Metastatic Sarcomatoid Renal Cell Carcinoma with the Combination of Gemcitabine, 5-Fluorouracil, and Interferon-Alfa: A Case Report of a 55-Yea...
- Mohs surgery in metastatic Cancer: renal cell carcinoma solitary cutaneous metastasis and visceral tumor metastases to skin treated with microscopically controlled sur...
- Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer.
- Radiofrequency ablation of Renal tumours with clinical, radiographical and pathological results.
- Illness Uncertainty and Quality of Life of Patients with Small Renal Tumors Undergoing Watchful Waiting: A 2-year Prospective Study.
- Energy Balance, Polymorphisms in the mTOR Pathway, and Renal Cell Carcinoma Risk.
- Reply from Authors re: Camillo Porta. How to Identify Active Novel Agents in Rare Cancers and then Make Them Available: A Need for a Paradigm Shift. Eur Urol 2012;62:1...
- Development of Accurate Models for Individualized Prediction of Survival After Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.
- The Impact of Tyrosine Kinase Inhibitors on the Multimodality Treatment of Brain Metastases From Renal Cell Carcinoma.
- Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell Carcinoma: role of inflammatory signaling.
- A Phase 2 Trial of Sunitinib in Patients with Advanced Non-clear Cell Renal Cell Carcinoma.
- Phase II Trial of Pemetrexed Plus Gemcitabine in Patients With Locally Advanced and Metastatic Nonclear Cell Renal Cell Carcinoma.
- Metastatic Extraosseous Ewing's Sarcoma (EES)/Primitive Neuroectodermal Tumor (PNET) of the Kidney: 8-Year Durable Response After Induction and Maintenance Chemotherapy.
- Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell Cancer after sunitinib failure.
- Pilot Trial of Bone-Targeted Therapy Combining Zoledronate With Fluvastatin or Atorvastatin for Patients With Metastatic Renal Cell Carcinoma.
- Chromophobe Renal Cell Carcinoma With Sarcomatoid Dedifferentiation Treated With Pazopanib: A Case Report.
- Emerging Targeted Therapies in Metastatic Renal Cell Carcinoma.
- Treatment-Related Optimism Protects Quality of Life in a Phase II Clinical Trial for Metastatic Renal Cell Carcinoma.
- Systemic therapy for metastatic non-clear-cell renal cell Carcinoma: recent progress and future directions.
- Early Primary Tumor Size Reduction Is an Independent Predictor of Improved Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib.
- Safety of Presurgical Targeted Therapy in the Setting of Metastatic Renal Cell Carcinoma.
- Durable remission of metastatic renal cell Carcinoma with gemcitabine and capecitabine after failure of targeted therapy.
- Metastasectomy after targeted therapy in patients with advanced renal cell Carcinoma.
- Thyroid-like follicular Carcinoma of the kidney with metastases to the lungs and retroperitoneal lymph nodes.
- Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell Carcinoma.
- Percutaneous biopsy of primary tumor in metastatic renal cell Carcinoma to predict high risk pathological features: comparison with nephrectomy assessment.
- Survival outcomes for men with mediastinal germ-cell tumors: The University of Texas M. D. Anderson Cancer Center experience.
- Can we better select patients with metastatic renal cell Carcinoma for cytoreductive nephrectomy?
- Perfusion CT in patients with metastatic renal cell Carcinoma treated with interferon.
- Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell Carcinoma: clinical and biomarker an...
- Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced Malignancies.
- Genome-wide profiling of chromosomal alterations in renal cell Carcinoma using high-density single nucleotide polymorphism arrays.
- Choroidal and conjunctival metastases from renal cell Carcinoma.
- Papillary renal cell Carcinoma: radiologic-pathologic correlation and spectrum of disease.
- Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection.
- Family history and risk of renal cell Carcinoma: results from a case-control study and systematic meta-analysis.
- Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell Carcinoma.
- Ischemic optic neuropathy associated with low-dose interferon alfa: report of two cases.
- Cutaneous squamous cell Carcinoma and inflammation of actinic keratoses associated with sorafenib.
- Malignant transformation of testicular teratoma: a chemoresistant phenotype.
- Renal cell Carcinoma: diagnosis, staging, and surveillance.
- A phase II trial of gemcitabine plus capecitabine for metastatic renal cell Cancer previously treated with immunotherapy and targeted agents.
- Multisystem crisis in a patient with presumptive renal cell Carcinoma.
- Sunitinib-induced acute hemolysis without hypertension: a case report.
- Adjuvant and neoadjuvant therapy in renal cell Carcinoma.
- Multiple squamous cell Carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
- Viable germ Cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression?
- Recurrence in nonseminomatous germ Cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection.
- Treatment outcomes of small cell Carcinoma of the prostate: a single-center study.
- Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate Cancer with bone metastases.
- Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal Cancer.
- Natural history of metastatic renal cell Carcinoma in patients who underwent consultation for allogeneic hematopoietic stem cell transplantation.
- Patient survival after surgery for osseous metastases from renal cell Carcinoma.
- Surgical management of growing teratoma syndrome: the M. D. Anderson Cancer center experience.
- Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection.
- Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose v...
- Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular Cancer.
- Viable Malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?
- Percutaneous radiofrequency ablation of renal Tumors: technique, complications, and outcomes.
- Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem Cell transp...
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- AdRenal Gland Cancer
- Anemia
- Bladder Cancer
- Carcinoma in Situ
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Choice Plus POS II
- Blue Card PPO
- Blue Choice
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- First Health (Coventry Health Care) PPO
- Choice Care PPO
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Awards
- Top Doctors:SE Texas
Education
-
University of Texas MD Anderson Cancer Center -
American University of Beirut Faculty of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1760588693 | |
| NPPES Provider LastName | TANNIR | |
| NPPES Provider FirstName | NIZAR | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 1075.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 82.0 | |
| Percent Opioid Claims | 7.63 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1760588693 |
| Last Name Of The Provider | TANNIR |
| First Name Of The Provider | NIZAR |
| View All |
Similar Doctors
|
|
Dr. Shagufta N. Naqvi, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kathryn A. Gold, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John Thachil, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Martin N. Raber, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bryan K. Kee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarvari V. Yellapragada, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nicholas E. Papadopoulos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jorge E. Cortes-Franco, MD |
|
|
Dr. Borje S. Andersson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John T. French, MD |
|
Dr. Luis H. Camacho, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Ajay Mitter, MD
This Doctor is OpenDoctor Recommended.
|